Opinion|Videos|September 11, 2024
Friedreich Ataxia: Looking Forward at the Treatment Landscape
Author(s)Susan Perlman, MD
A Friedreich ataxia specialist shares their optimistic outlook on future developments in the management of the condition.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you see the management of FA changing in the future?
Advertisement
Related to this article
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5